These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 1630667)

  • 1. [4'-epidoxorubicin: its cardiotoxicity. Possible cardiac protection with gallopamil, a drug with calcium-antagonist action].
    Polverino W; Basso A; Bonelli A; Muto P; Cittadini A; Salvatore M
    Minerva Cardioangiol; 1992; 40(1-2):23-30. PubMed ID: 1630667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary echocardiographic and polygraphic evaluation of cardiac toxicity of 4'-epi-doxorubicin.
    Villani F; Comazzi R; Lacaita G; Genitoni V; Guindani A; Martini A
    Int J Clin Pharmacol Ther Toxicol; 1983 Apr; 21(4):203-8. PubMed ID: 6574995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The evaluation of the cardiotoxicity of 4'-epidoxorubicin at high doses].
    Mengozzi G; Palagi C; Petronio AS; Balbarini A; Mariotti R; Macchiarini P; Angeletti CA; Del Tacca M; Squartini F; Mariani M
    Cardiologia; 1991 Feb; 36(2):137-42. PubMed ID: 1661205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microperfusion in coronary artery disease under treatment with the calcium antagonist gallopamil.
    Eichstädt H; Danne O; Gutmann M; Langer M; Felix R; Schmutzler H
    Arzneimittelforschung; 1988 May; 38(5):700-3. PubMed ID: 3415712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A functional assessment of the relative cardiotoxicity of adriamycin and epirubicin in the rat.
    Yeung TK; Simmonds RH; Hopewell JW
    Radiother Oncol; 1989 Jul; 15(3):275-84. PubMed ID: 2772255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative evaluation of the cardiotoxic effects of antineoplastic antibiotics adriamycin and pharmorubicin].
    Valvere VIu; Shkhvatsabaia LV; Niu-Tian-de GB
    Kardiologiia; 1989 Sep; 29(9):64-7. PubMed ID: 2687558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preischaemic as well as postischaemic application of a calcium antagonist affords cardioprotection in the isolated guinea pig heart.
    Massoudy P; Becker BF; Seligmann C; Gerlach E
    Cardiovasc Res; 1995 Apr; 29(4):577-82. PubMed ID: 7796453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary evaluation of myocardial toxicity of 4'-deoxydoxorubicin: experimental and clinical results.
    Villani F; Comazzi R; Genitoni V; Lacaita G; Guindani A; Crippa F; Monti E; Piccinini F; Rozza A; Lanza E
    Drugs Exp Clin Res; 1985; 11(3):223-31. PubMed ID: 3836127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-term treatment of stable angina pectoris with gallopamil].
    Pupita G; Mattei O; Mazzara D; Centanni M; Ferretti GF; Rimatori C; Dessì-Fulgheri P; Rappelli A; Russo P
    G Ital Cardiol; 1992 Sep; 22(9):1049-56. PubMed ID: 1291422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti-ischemia effects of gallopamil and esmolol in an intra-individual comparison in patients with coronary heart disease].
    Mitrovic V; Oehm E; Minge C; Thürmann P; Schlepper M
    Z Kardiol; 1994 Jun; 83(6):431-8. PubMed ID: 7915067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gallopamil: cardiovascular scope of action of a highly specific calcium antagonist.
    Fleckenstein-Grün G
    J Cardiovasc Pharmacol; 1992; 20 Suppl 7():S1-10. PubMed ID: 1284148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of gallopamil on cardiac sarcoplasmic reticulum.
    Zucchi R; Ronca-Testoni S; Limbruno U; Yu G; Galbani P; Ronca G; Mariani M
    J Cardiovasc Pharmacol; 1992; 20 Suppl 7():S11-5. PubMed ID: 1284150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic coronary effectiveness of retard gallopamil following repeated administration in comparison with placebo].
    Loskot F; Novotny P; Sucic P; Schneider G
    Z Kardiol; 1989; 78 Suppl 5():89-93. PubMed ID: 2698569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of gallopamil on myocardial perfusion in angina of effort].
    Musso P; Ottello B; Pinnavaia A; Giammaria M; Mussio R; Aquaro G
    Minerva Cardioangiol; 1992 Mar; 40(3):97-103. PubMed ID: 1630681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin and epirubicin cardiotoxicity: experimental and clinical aspects.
    Neri B; Cini-Neri G; Bandinelli M; Pacini P; Bartalucci S; Ciapini A
    Int J Clin Pharmacol Ther Toxicol; 1989 May; 27(5):217-21. PubMed ID: 2737789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Gallopamil in stable effort angina. Effects of 2 different dosages].
    Sangiorgio P; Rubboli A; Brunelli D; Bracchetti D
    G Ital Cardiol; 1989 Jan; 19(1):40-5. PubMed ID: 2744313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies.
    Salvatorelli E; Menna P; Gianni L; Minotti G
    J Pharmacol Exp Ther; 2007 Feb; 320(2):790-800. PubMed ID: 17135345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical study of acute cardiotoxicity of anti-cancer agents-- analysis using Holter ECG monitoring].
    Okuma K; Ariyoshi Y; Ota K
    Gan To Kagaku Ryoho; 1988 Jun; 15(6):1893-900. PubMed ID: 3164181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary clinical experience with 4-epidoxorubicin in advanced human neoplasia.
    Bonfante V; Bonadonna G; Villani F; Martini A
    Recent Results Cancer Res; 1980; 74():192-9. PubMed ID: 6934564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.